Circio’s circVec 5.2 design achieves up to 200 times higher gene expression in cardiac tissue than conventional AAV vectors, with 95% cardiac specificity.
Circio presents three talks at ESGCT highlighting its **AAV circVec 5.2** design, which aims to improve heart-specific gene expression and precision in therapies. The Oslo-based biotech shares updates on its circular RNA technology for gene and cell therapy applications. Presentations include oral and poster formats at the 33rd Annual Congress in Hamburg.
Circio secures approximately **NOK 200 million** in new funding to advance its **in vivo CAR-T therapy program**, a next-generation approach to treating cancer by engineering immune cells inside the body. The capital supports preclinical development and clinical trials, positioning Circio as a leader in **in situ** cell therapy innovations. The company aims to streamline CAR-T production compared to traditional ex vivo methods.
Circio Holding ASA, a biotechnology firm specializing in circular RNA technology for nucleic acid medicine, reports strong progress in research and development, financing, and business growth for the first half of 2026. The company will detail updated R&D results in a live webcast on September 1, 2026. Key advancements in its pipeline and strategic partnerships are expected to be highlighted.
Circio and Full Circles Therapeutics are collaborating to evaluate combining Circio’s **circVec circular RNA expression technology** with Full Circles’ **non-viral, immune-evasive DNA writing platform** for next-generation **in vivo cell therapy**. The partnership aims to advance gene and cell therapy approaches by integrating their respective technologies. Both companies specialize in non-viral methods to enhance therapeutic delivery and efficacy.
Circio and AaviGen collaborate to develop **circVec-enhanced AAV vectors** for targeted, low-dose gene therapy in heart diseases. The partnership combines Circio’s circular RNA expression technology with AaviGen’s precision cardiac gene therapy expertise. Both companies aim to advance novel treatments for human cardiac conditions through this joint research effort.
Circio Holding ASA files a new patent application with the European Patent Office (EPO) for its **circVec platform**, a circular RNA expression technology designed to advance gene and cell therapy. The company plans to expand the filing under the Patent Cooperation Treaty (PCT) globally. This move secures intellectual property for a key innovation in therapeutic delivery methods.
Circio
Circio is a biotechnology company developing circular RNA medicines with circVec for AAV gene therapy and in vivo CAR-T.